Trial Profile
A Retrospective study of consecutive patients treated with BioMimea Sirolimus Eluting Coronary Stent System during a pre-defined period. - MeriT-lll A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2020
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors Meril Life Sciences
- 15 Dec 2017 New trial record